Why Amgen Inc. (AMGN) is One of the Best Stem Cell Therapy Stocks to Buy

robot
Abstract generation in progress

Amgen Inc. (NASDAQ: AMGN) is highlighted as a top stem cell therapy stock, following Canaccord’s initiation of coverage with a Hold rating and a $366 price target. While the company has shown strong financial performance with double-digit revenue and EPS growth in fiscal Q4 and full year 2025 results, its current valuation is deemed appropriate, with future appreciation potentially challenged by loss of exclusivities and pricing pressure. Amgen specializes in developing and marketing human therapeutics for complex cancers.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin